ABSTRACT -The antidiabetic agent troglitazone was given to groups of 4 cynomolgus monkeys per sex at 300, 600, or 1200 mg/kg daily by gavage for 52 weeks. A group of 4 monkeys per sex received vehicle alone and served as controls. Emesis and soft stool or diarrhea occurred sporadically in all troglitazone-treated groups, but did not compromise animal health. There were no effects on body weight or food consumption, or ophthalmologic, electrocardiographic, or echocardiographic parameters. Erythrocyte count, hemoglobin, and hematocrit decreased 8% to 16% in males at all doses and serum cholesterol decreased 30% to 46% in both sexes at all doses. Urinary ketones were increased in several animals at 600 and 1200 mg/kg. Absolute and relative liver weights increased at all doses in both sexes by 40% to 71%. The only microscopic change attributable to troglitazone treatment was minimal to mild bile duct hyperplasia in males at all doses and in females at 600 and 1200 mg/kg. No differences in systemic exposure were apparent between sexes. Over the dose range tested, AUC values were 27 to 102 µg·hr/ml of troglitazone, 401 to 2060 µg·hr/ml of its sulfate conjugate, and 34 to 312 µg·hr/ ml of its quinone metabolite. Therefore, oral administration of troglitazone to monkeys at 300, 600, and 1200 mg/kg for 52 weeks resulted in significant systemic exposure, with only minimal gastrointestinal, hematologic, and hepatic effects.
INTRODUCTION
Intensive treatment of type 2 diabetes provides unequivocal evidence that glycemic control is critical in reducing the risk of long-term complications (The Diabetes Control and Complications Trial Research Group, 1993; Ohkubo et al., 1995; UK Prospective Diabetes Study Group, 1998) . Troglitazone is a member of the thiazolidinedione chemical class, unrelated chemically or functionally to the sulfonylurea or biguanide oral antidiabetic agents. Troglitazone binds and activates the peroxisome proliferator-activated receptor-gamma (PPAR-γ), a mechanism believed to mediate increased glucose utilization, reduced hepatic glucose production, and enhanced insulin sensitivity (Saltiel and Horikoshi, 1995; Saltiel and Olefsky, 1996) . Prior to troglitazone's withdrawal from the market, it was used concomitantly with a sulfonylurea or insulin, enabling many patients to achieve, for the first time, American Diabetes Association goals for glycemic control (Horton et al., 1998) . The recommended human dose effective in most patients was 200 or 400 mg once daily, with associated exposures (AUC ) of approximately 13 µg·hr/ml. Pharmacokinetic data indicate that troglitazone metabolites identified in humans (M-1, sulfate conjugate; M-2, glucuronide conjugate; and M-3, a quinone) are also found in monkeys (Brodfuehrer et al., 1993; Horikoshi et al., 1994; Izumi et al., 1996; Loi et al., 1997) . In addition, the relative proportions of troglitazone, M-1, M-2, and M-3 metabolites in humans are similar to those in monkeys.
The development of troglitazone was a progressive process involving an evaluation of both animal and human safety information. Animal data were used initially to establish a safe starting dose for human trials, and to identify parameters for monitoring potential adverse effects. The objective of this study was to characterize potential toxicity of troglitazone when given orally to male and female cynomolgus monkeys daily for 52 weeks at doses that resulted in maximal systemic exposure to troglitazone and metabolites (Rothwell et al., 1997) . The study was conducted at MPI Research (formerly International Research and Development Corporation), Mattawan, Michigan, and was in compliance with US FDA Good Laboratory Practice regulations.
MATERIALS AND METHODS

Animals and housing
Cynomolgus monkeys (Macaca fascicularis) were 2 to 6 years old and weighed 2.6 to 3.5 kg at study initiation. They were individually housed in stainless steel cages that were changed every 2 weeks. The room was maintained at 18-27°C and 32-74% relative humidity, with 12 hr of light and 12 hr of darkness. Purina Certified Primate Chow 5048 and water were provided ad libitum. Diet was supplemented with Primatreats ® , popcorn, cereals, fruits, and vegetables.
Test substance
Troglitazone (USAN; INN) is a member of the thiazolidinedione chemical class (Fig. 1) and is chemically described as (±)-5- [[4-[(3,4-dihydro-6-hydroxy-2,5,7,8 -tetramethyl-2H-1-benzopyran-2-yl)methoxy]phenyl]methyl]-2,4-thiazolidinedione. The troglitazone formulation used in this 52-week monkey study was an amorphous coprecipitate with povidone, polyethylene glycol 400, and polysorbate 80, the same formulation used in the marketed product Rezulin ® . Doses were based on active drug moiety of 56.7%. Troglitazone was shown to be homogeneous and stable in vehicle, 0.5% methylcellulose, over the concentration range used. Bulk drug retained potency throughout the study.
Treatment and clinical evaluation
Groups of 4 monkeys per sex were given daily gavage doses of troglitazone in 0.5% methylcellulose at 300, 600, or 1200 mg/kg for 52 weeks. Dose volume was 10 ml/kg. Another group of 4 monkeys per sex received vehicle at 10 ml/kg and served as controls. Animals were observed twice daily for clinical signs of toxicity; detailed physical examinations were performed pretest and at 1, 3, 6, 9, and 12 months. Body weights were recorded weekly and food consumption was assessed daily. Electrocardiograms were recorded during Week 3 and at 3, 6, 9, and 12 months. Ophthalmoscopic and echocardiographic examinations were conducted pretest and at 6 and 12 months. Echocardiographic measurements included left ventricular internal dimension diastole (LVIDd) and systole (LVIDs), left ventricular posterior wall diastole (PWd) and systole (PWs), interventricular septum diastole (IVSd) and systole (IVSs), E point to septal separation (ESS), and aortic diameter (AD).
Clinical and diagnostic pathology
Blood for hematology and clinical biochemistry analyses was collected from fasted animals pretest and at 3, 6, 9, and 12 months. Urinalysis was conducted on samples collected pretest and at 6 and 12 months. Bone marrow smears were prepared at necropsy. Protocolspecified organs were weighed and tissues from all animals were examined microscopically.
Toxicokinetic analyses
Blood samples were collected from all monkeys pretest and at 1, 2, 4, 8, and 24 hr postdose during Weeks 2, 13, and 52. Plasma was analyzed for troglitazone and metabolites M-1 (sulfate conjugate) and M-3 (±)-5- [[4-[(3,4-dihydro-6-hydroxy-2,5,7,8- Vol. 27 No. 1 (quinone). Exposures of troglitazone and metabolites are expressed as C max (maximum plasma concentration (µg/ml)) and AUC (area under the plasma concentration-time curve from 0 to 24 hr (µg·hr/ml)).
Statistical analyses
Body weights, hematology, biochemistry, and urinalysis parameters and absolute and relative (to body and brain weights) organ and tissue weights were analyzed using one-way analysis of variance (one-way classification). If no significance was observed, no further analysis was evaluated. If significance was observed, Bartlett's test (Steel and Torrie, 1980) for the homogeneity of variances was evaluated. Treatment groups were compared to the control group, by sex, using the appropriate t-test (for equal or unequal variances). Dunnett's multiple comparison tables (Dunnett, 1964) or the Welch t-test (Welch, 1938 ) with a Bonferroni correction (Neter and Wasserman, 1974) were used to determine the significance of differences. Where nonparametric statistical procedures were appropriate, rank transformation (Conover and Iman, 1981) was conducted on the data and an analysis of variance was performed on the ranks. If the analysis of variance was not significant, no further analysis was evaluated. If the analysis of variance was significant, then the Mann-Whitney U-Test (Siegel, 1956 ) was evaluated. All statistical analyses were performed with p≤0.01 used as level of significance. For echocardiographic parameters, 6-and 12-month rank-transformed data were analyzed by sequential linear trend test, oneand/or two-tailed, at a 5% classwise significance level. A trend reversal test was also performed.
Dose selection rationale
Crystalline troglitazone was well tolerated when given to monkeys at doses of 50 to 800 mg/kg/day for up to 52 weeks (Sudou and Mori, 1993; Mayfield et al., 1993) . Decreased serum cholesterol and increased liver weight in both sexes at 800 mg/kg were the only drug-related effects. Since increased exposures were observed in rodents with amorphous troglitazone in comparison with crystalline troglitazone (Herman et al., 1997; McGuire et al., 1997) , toxicology studies in monkeys were repeated to maximize exposure. In 2-and 13-week studies, amorphous troglitazone did not induce clinical signs, deaths, or changes in body weight, food consumption, electrocardiographic or hematology parameters. Increased liver weight without concomitant histopathologic change was observed at 200, 400, and 800 mg/kg after 13 weeks. Based on these studies, the highest achievable dose based on dose volume and solubility limitations (1200 mg/kg) was selected as the high dose in this definitive chronic study. Additional doses of 300 and 600 mg/kg were selected to investigate dose-response relationships.
RESULTS
Clinical evaluations
In the 52-week monkey study at doses of amorphous troglitazone of 300, 600, and 1200 mg/kg, there were no deaths or effects on body weight or food consumption. Emesis and soft feces or diarrhea occurred sporadically at all doses. No other drug-related clinical signs were observed and all monkeys survived to scheduled termination. There were no effects on body weight, food consumption, ophthalmologic or electrocardiographic parameters. No significant changes in echocardiographic parameters were observed (Table  1) , and no changes in contractility of the ventricles, either segmental or generalized, were apparent.
Clinical laboratory tests
Erythrocyte count, hemoglobin, and hematocrit decreased 8% to 16% in males at all doses (Table 2) . No drug-related effects on bone marrow were apparent (Table 3) . Serum cholesterol decreased 30% to 46% in both sexes at all doses (Table 4 ). There were no significant changes in clinical biochemistry parameters indicative of liver injury (Table 4) . Urinary ketones were present in a 600 mg/kg female and a 1200 mg/kg male at 6 months and in several 600 and 1200 mg/kg monkeys at 12 months.
Pathology
No drug-related gross pathologic abnormalities were observed. Absolute and relative liver weights were increased at all doses in both sexes (Table 5) . Weights were increased 40% to 56% at 300 and 600 mg/kg in comparison with controls, and 59% to 71% at 1200 mg/kg. Bile duct hyperplasia was present at all doses and both incidence and severity increased with increasing dose; severity was generally minimal or mild. Appearance and weight of interscapular brown adipose tissue and heart weight were similar in troglitazone-treated and control monkeys. No other microscopic changes attributable to troglitazone-treatment were apparent.
Toxicokinetic analyses
Toxicokinetic parameters of troglitazone and metabolites M-1 and M-3 are presented in Table 6 . Mean plasma troglitazone, M-1, and M-3 concentrations in male and female monkeys were variable and there were no apparent sex differences. C max values did not increase consistently with dose; however, there was a small increase in mean AUC values from 300 to 1200 mg/kg. Mean troglitazone, M-1, and M-3 AUC values decreased from Weeks 2 to 13. At Week 52, values were comparable to or slightly lower than those obtained in Week 2. For all weeks combined, AUC values for troglitazone, M-1, and M-3 ranged from 27 to 102, 401 to 2060, and 34 to 312 µg·hr/ml, respectively.
DISCUSSION
Exposures to troglitazone, M-1, and M-3 in the 52-week study with amorphous troglitazone ranged from approximately 3 to 6, 6 to 13, and 4 to 10 times, respectively, those in humans given 400 mg daily. At maximal achievable doses, monkeys remained in excellent health for 52 weeks. The sporadic instances of emesis and soft feces or diarrhea did not affect body weight, serum electrolytes, or general physical condi- tion, and may have been a consequence of the large volume of material that was administered daily. The decrease in serum cholesterol in monkeys at all doses in both sexes is considered a pharmacologic effect. Previous studies demonstrated effects of thiazolidinediones on lipid metabolism in both insulin-resistant animals (Fujiwara et al., 1988; Lee et al., 1994; Bowen et al., 1991; Kazumi et al., 1996) and humans (Iwamoto et al., 1995 and Maggs et al., 1998) . Thiazolidinediones are also known to be potent and specific ligands of peroxisome proliferator-activated receptor γ (PPARγ), which is directly involved in the regulation of genes controlling glucose homeostasis, adipocyte differentiation, and/or lipid metabolism (Saltiel and Horikoshi, 1995; Saltiel and Olefsky, 1996) . The precise roles of PPAR receptors in the bio- logical actions of thiazolidinediones are yet to be resolved. Lipid-lowering effects may result from a direct action on the liver, or perhaps indirectly, from the reduction of plasma insulin and free fatty acid levels. Lipid changes appear to reflect a correlation between hyperglycemia and dyslipidemia (Wood, 1995; Horton et al., 1998) . Significant decreases in erythrocyte count, hemoglobin, and hematocrit apparent in male monkeys also occur in rodents given troglitazone (Horikoshi et al., 1994; Herman et al., 1997; McGuire et al., 1997; de la Iglesia et al., 1998) and have been attributed to hemodilution due to increased plasma volume. In rats, troglitazone treatment was associated with increases of 6% to 15% in plasma volume. Bone marrow erythropoiesis was not affected, isotropic chromium labeling techniques failed to demonstrate a significant decrease in circulating erythrocytes, and Evans blue dilution techniques revealed significant increases in plasma volume. Thus, decreases in erythrocyte parameters do not reflect actual decreases in cell number, but are attributed to fluid retention. This hemodilution is apparently independent of several hormones, including plasma renin activity and aldosterone. Similar effects on erythrocyte parameters have also been reported with insulin, known to stimulate water and sodium retention (Hall et al., 1992) . It is not known if the hemodilution that occurs in rats with both thiazolidinediones and insulin is the result of a similar mechanism. In controlled clinical trials, an increase in plasma volume of 6% to 8% compared to placebo was observed following 6 weeks of treatment, but there was no increase in adverse events potentially related to volume expansion Horton et al., 1998; Maggs et al., 1998) . Increased liver weight, a consistent finding in preclinical toxicology studies in mice, rats, and monkeys (Horikoshi et al., 1994; Herman et al., 1997; McGuire et al., 1997; Rothwell et al., 1997; de la Iglesia et al., 1998) has been attributed, at least in part, to cytochrome P450 enzyme induction. In addition to the reversible increases in liver weight and hepatocellular hypertrophy, troglitazone increases hepatic CYP, due primarily to induction of CYP2B and CYP4A in rodents and CYP2B in monkeys. Consistent with the CYP induction, morphologic and biochemical evidence of minimal hepatic peroxisomal enzyme induction occurs in rodents, but not in monkeys. Bile duct hyperplasia, generally minimal to mild in severity, occurred at all doses. These hepatic effects appear to reflect functional adaptation associated with the metabolism and excretion of troglitazone. No evidence of hepatocyte injury or fibrosis was apparent. Hepatic dysfunction has been reported in a limited number of patients (Kuramoto et al., 1998; Watkins and Whitcomb, 1998) . However, hepatic injury was not apparent in monkeys treated chronically at high exposures, or in other species used to define the toxicology a Samples obtained 1, 2, 4, 8, and 24 hr postdose; mean, n=4. C max = Maximum plasma concentration (mg/ml). AUC (0-24) = Area under the plasma concentration-time curve from 0 to 24 hr (mg . hr/ml).
profile in animals (Horikoshi et al., 1994; Herman et al., 1997; McGuire et al., 1997; de la Iglesia et al., 1998) . Histopathologic reevaluation of liver from this chronic toxicity study in monkeys, and the chronic and carcinogenicity studies in rodents (Herman et al., 1997 and McGuire et al., 1998) confirmed liver dysfunction was not induced in experimental animals (Watanabe et al., 1999) . Interscapular brown adipose tissue was variable in size and appearance, but there was no evidence of increased weight in troglitazonetreated monkeys, in contrast with findings in rodents (Herman et al., 1997; McGuire et al., 1997; de la Iglesia et al., 1998) . Increased heart weight without microscopic change was observed in rodents at exposures of parent drug and active metabolite exceeding 7 times the AUC of the 400 mg human dose (Herman et al., 1997; McGuire et al., 1997) . No change in heart size or cardiac function was apparent in monkeys treated chronically in this study at maximum achievable exposures approximately 4 to 9 times the human exposure to troglitazone and active metabolite at the 400-mg dose, despite significant efforts to detect any possible effect in monkeys. Therefore, there were no treatmentrelated cardiac effects in monkeys based on heart weight, histopathology, and serial echocardiographic evaluations and electrocardiography. In a 2-year echocardiographic study at doses of 600 to 800 mg daily in patients with type 2 diabetes, there was no change in left ventricular mass or decrease in cardiac output, and no adverse cardiac events (Ogihara et al., 1995; Driscoll et al., 1997; Ghazzi et al., 1997) . However, there were beneficial effects, significant increases in stroke volume and cardiac output, and a significant decrease in diastolic blood pressure resulting from decreased peripheral resistance.
In summary, oral administration of troglitazone to monkeys at doses up to 1200 mg/kg for 52 weeks, resulting in significant systemic exposure, induced only minimal gastrointestinal, hematologic, and hepatic effects, with no indication of liver toxicity or cardiac enlargement.
